Decitabine Treatment for Melanoma Reveals Crucial Promoter Characteristics

Researchers have made a significant discovery in the treatment of melanoma, a type of skin cancer, by identifying key characteristics of promoter regions that define susceptibility to the epigenetic agent decitabine. In a study published in the journal BMC Medical Genomics, J.C. Rubinstein and colleagues from Yale University found that the combination of promoter CpG content and methylation level is crucial in determining whether decitabine treatment can up-regulate gene expression. This breakthrough has the potential to aid in predicting the likelihood of up-regulating epigenetically silenced tumor suppressor genes and others from pathways involved with tumor biology.

Key Takeaways:

The study identified a correlation between promoter CpG content and methylation level, and the ability of decitabine treatment to up-regulate gene expression.
Promoters with high methylation levels and intermediate CpG content are most susceptible to up-regulation by decitabine.
Few highly methylated promoters with high CpG content are up-regulated by decitabine, while those with low CpG content are underrepresented among up-regulated genes.
A classifier was built to predict gene up-regulation based on promoter methylation and CpG content, achieving a performance of 0.77 AUC.
The study used genome-wide gene expression data from melanoma cell strains, genome-wide data on un-treated promoter methylation status, and validation of specific genes by bisulfite sequencing.
The findings have the potential to aid in predicting the likelihood of up-regulating epigenetically silenced tumor suppressor genes and others from pathways involved with tumor biology.

Statistics:

0.77 AUC performance of the classifier built to predict gene up-regulation based on promoter methylation and CpG content.
3()():4 is the journal article reference in BMC Medical Genomics.

Sources:

Rubinstein, J.C. et al. (2010). Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma. BMC Medical Genomics, 3(), 4.